SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Open Access
- 20 March 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (19), 1801-1803
- https://doi.org/10.1093/eurheartj/ehaa235
Abstract
In a rapid response published online by the British Medical Journal, Sommerstein and Gräni1 pushed forward the hypothesis that angiotensin-converting enzyme (ACE) inhibitors (ACE-Is) could act as a potential risk factor for fatal Corona virus disease 2019 (COVID-19) by up-regulating ACE2. This notion was quickly picked up by the lay press and sparked concerns among physicians and patients regarding the intake of inhibitors of the renin–angiotensin–aldosterone system (RAAS) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infected individuals.1 In this article, we try to shed light on what is known and unknown regarding the RAAS and SARS-CoV2 interaction. We find translational evidence for diverse roles of the RAAS, which allows to formulate also the opposite hypothesis, i.e. that inhibition of the RAAS might be protective in COVID-19.This publication has 24 references indexed in Scilit:
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder StudyEuropean Heart Journal, 2014
- Pathology and Pathogenesis of Severe Acute Respiratory SyndromeThe American Journal of Pathology, 2007
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionThe New England Journal of Medicine, 2003
- Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial InfarctionCirculation, 1998
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 1995
- Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinaprilJournal of the American College of Cardiology, 1993